{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:02:24Z","timestamp":1784952144827,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute and the National Center for Advancing Translational Sciences of the NIH","award":["CCSG P30CA016672-46 and CCTS UM1TR004906"],"award-info":[{"award-number":["CCSG P30CA016672-46 and CCTS UM1TR004906"]}]},{"name":"The Dan Hund Memorial to Stomp Out Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12022-026-09927-x","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:36:58Z","timestamp":1784273818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-9615","authenticated-orcid":false,"given":"Vania","family":"Balderrama-Brondani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Marcal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Jad","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Waguespack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-9637","authenticated-orcid":false,"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"4","key":"9927_CR1","doi-asserted-by":"publisher","first-page":"G1-G46","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4):G1-G46. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"9927_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","volume":"13","author":"M Fassnacht","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M (2025) Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol 13(5):438\u201352. https:\/\/doi.org\/10.1016\/S2213-8587(24)00378-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"9927_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/PAS.0000000000000943","volume":"42","author":"O Mete","year":"2018","unstructured":"Mete O, Gucer H, Kefeli M, Asa SL (2018) Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. Am J Surg Pathol 42(2):201\u201313. https:\/\/doi.org\/10.1097\/PAS.0000000000000943","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"9927_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, et al (2022) Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol 33(1):155\u201396. https:\/\/doi.org\/10.1007\/s12022-022-09710-8","journal-title":"Endocr Pathol"},{"issue":"3","key":"9927_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1210\/jc.2014-3182","volume":"100","author":"F Beuschlein","year":"2015","unstructured":"Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al (2015) Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100(3):841\u20139. https:\/\/doi.org\/10.1210\/jc.2014-3182","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9927_CR6","doi-asserted-by":"publisher","first-page":"e307-18","DOI":"10.1210\/clinem\/dgz141","volume":"105","author":"V Chortis","year":"2020","unstructured":"Chortis V, Bancos I, Nijman T, Gilligan LC, Taylor AE, Ronchi CL, et al (2020) Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab 105(3):e307-18. https:\/\/doi.org\/10.1210\/clinem\/dgz141","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9927_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/metabo14010020","volume":"14","author":"O Kimpel","year":"2023","unstructured":"Kimpel O, Altieri B, Dischinger U, Fuss CT, Kurlbaum M, Fassnacht M (2023) Early Detection of Recurrence and Progress Using Serum Steroid Profiling by LC-MS\/MS in Patients with Adrenocortical Carcinoma. Metabolites 14(1): 20. https:\/\/doi.org\/10.3390\/metabo14010020","journal-title":"Metabolites"},{"issue":"3","key":"9927_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ejendo\/lvae022","volume":"190","author":"J Lippert","year":"2024","unstructured":"Lippert J, Smith G, Appenzeller S, Landwehr LS, Prete A, Steinhauer S, et al (2024) Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma. Eur J Endocrinol 190(3):234\u201347. https:\/\/doi.org\/10.1093\/ejendo\/lvae022","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"9927_CR9","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1210\/jc.2017-00174","volume":"102","author":"SG Creemers","year":"2017","unstructured":"Creemers SG, Korpershoek E, Atmodimedjo PN, Dinjens WNM, van Koetsveld PM, Feelders RA, et al (2017) Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series. J Clin Endocrinol Metab 102(10):3611\u20135. https:\/\/doi.org\/10.1210\/jc.2017-00174","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9927_CR10","doi-asserted-by":"publisher","first-page":"L13-L7","DOI":"10.1530\/ERC-17-0467","volume":"25","author":"S Garinet","year":"2018","unstructured":"Garinet S, Nectoux J, Neou M, Pasmant E, Jouinot A, Sibony M, et al (2018) Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. Endocr Relat Cancer 25(3):L13-L7. https:\/\/doi.org\/10.1530\/ERC-17-0467","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"9927_CR11","doi-asserted-by":"publisher","first-page":"a003764","DOI":"10.1101\/mcs.a003764","volume":"5","author":"MJ McCabe","year":"2019","unstructured":"McCabe MJ, Pinese M, Chan CL, Sheriff N, Thompson TJ, Grady J, et al (2019) Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Cold Spring Harb Mol Case Stud 5(2):a003764. https:\/\/doi.org\/10.1101\/mcs.a003764","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"3","key":"9927_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1507\/endocrj.EJ24-0346","volume":"72","author":"D Aono","year":"2025","unstructured":"Aono D, Kato T, Morisawa A, Kimata S, Konishi S, Kometani M, et al (2025) Adrenocortical carcinoma with circulating tumor DNA analysis at post-operative recurrence: a case report with review of literature. Endocr J. 2025;72(3):325\u2009\u2013\u200932.https:\/\/doi.org\/10.1507\/endocrj.EJ24-0346","journal-title":"Endocr J"},{"issue":"1\u20132","key":"9927_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0009-8981(01)00665-9","volume":"313","author":"M Stroun","year":"2001","unstructured":"Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313(1\u20132):139\u201342. https:\/\/doi.org\/10.1016\/s0009-8981(01)00665-9","journal-title":"Clin Chim Acta"},{"issue":"3","key":"9927_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","volume":"35","author":"AR Thierry","year":"2016","unstructured":"Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M (2016) Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 35(3):347\u201376. https:\/\/doi.org\/10.1007\/s10555-016-9629-x","journal-title":"Cancer Metastasis Rev"},{"key":"9927_CR15","doi-asserted-by":"publisher","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","volume":"157","author":"Z Hu","year":"2021","unstructured":"Hu Z, Chen H, Long Y, Li P, Gu Y (2021) The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. Crit Rev Oncol Hematol 157:103166. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103166","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"9927_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"9927_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985\u201390. https:\/\/doi.org\/10.1038\/nm.1789","journal-title":"Nat Med"},{"issue":"9","key":"9927_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14(9):531\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2017.14","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"9927_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","volume":"22","author":"N Normanno","year":"2025","unstructured":"Normanno N, Morabito A, Rachiglio AM, Sforza V, Landi L, Bria E, et al (2025) Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? Nat Rev Clin Oncol 22(3):215\u201331. https:\/\/doi.org\/10.1038\/s41571-024-00985-w","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"9927_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabieres C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"9927_CR21","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1038\/s41467-021-25432-7","volume":"12","author":"SY Cindy Yang","year":"2021","unstructured":"Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, et al (2021) Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun 12(1):5137. https:\/\/doi.org\/10.1038\/s41467-021-25432-7","journal-title":"Nat Commun"},{"issue":"7867","key":"9927_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al (2021) ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595(7867):432\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03642-9","journal-title":"Nature"},{"key":"9927_CR23","doi-asserted-by":"publisher","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","volume":"6","author":"F Cailleux","year":"2022","unstructured":"Cailleux F, Agostinetto E, Lambertini M, Rothe F, Wu HT, Balcioglu M, et al (2022) Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precis Oncol 6:e2200148. https:\/\/doi.org\/10.1200\/PO.22.00148","journal-title":"JCO Precis Oncol"},{"issue":"7969","key":"9927_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen SA, Liu MC, Aleshin A (2023) Practical recommendations for using ctDNA in clinical decision making. Nature 619(7969):259\u201368. https:\/\/doi.org\/10.1038\/s41586-023-06225-y","journal-title":"Nature"},{"issue":"11","key":"9927_CR25","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, et al (2023) Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer 129(11):1723\u201334. https:\/\/doi.org\/10.1002\/cncr.34716","journal-title":"Cancer"},{"key":"9927_CR26","doi-asserted-by":"publisher","first-page":"e2300131","DOI":"10.1200\/PO.23.00131","volume":"7","author":"A Jang","year":"2023","unstructured":"Jang A, Lanka SM, Jaeger EB, Lieberman A, Huang M, Sartor AO, et al (2023) Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. JCO Precis Oncol 7:e2300131. https:\/\/doi.org\/10.1200\/PO.23.00131","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"9927_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ucl.2022.09.010","volume":"50","author":"I Madueke","year":"2023","unstructured":"Madueke I, Lee RJ, Miyamoto DT (2023) Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers. Urol Clin North Am 50(1):109\u201314. https:\/\/doi.org\/10.1016\/j.ucl.2022.09.010","journal-title":"Urol Clin North Am"},{"issue":"26","key":"9927_CR28","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.23.02054","volume":"42","author":"T Akaike","year":"2024","unstructured":"Akaike T, Thakuria M, Silk AW, Hippe DS, Park SY, So NA, et al (2024) Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications. J Clin Oncol 42(26):3151\u201361. https:\/\/doi.org\/10.1200\/JCO.23.02054","journal-title":"J Clin Oncol"},{"key":"9927_CR29","doi-asserted-by":"publisher","first-page":"e2400281","DOI":"10.1200\/PO.24.00281","volume":"8","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Alerasool P, Kalola H, Tillu N, Almoflihi M, Tsao CK, et al (2024) Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma. JCO Precis Oncol 8:e2400281. https:\/\/doi.org\/10.1200\/PO.24.00281","journal-title":"JCO Precis Oncol"},{"key":"9927_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/1750743X.2024.2430941","volume":"16","author":"N Burley","year":"2024","unstructured":"Burley N, Lee Y, Liu L, Gangi A, Nasseri Y, Atkins K, et al (2024) ctDNA-guided adjuvant immunotherapy in colorectal cancer. Immunotherapy 16(20\u201322):1197\u2013202. https:\/\/doi.org\/10.1080\/1750743X.2024.2430941","journal-title":"Immunotherapy"},{"issue":"9","key":"9927_CR31","doi-asserted-by":"publisher","first-page":"103687","DOI":"10.1016\/j.esmoop.2024.103687","volume":"9","author":"R Cutts","year":"2024","unstructured":"Cutts R, Ulrich L, Beaney M, Robert M, Coakley M, Bunce C, et al (2024) Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. ESMO Open 9(9):103687. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103687","journal-title":"ESMO Open"},{"issue":"15","key":"9927_CR32","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","volume":"30","author":"GJ Hanna","year":"2024","unstructured":"Hanna GJ, Dennis MJ, Scarfo N, Mullin MS, Sethi RKV, Sehgal K, et al (2024) Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 30(15):3329\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0590","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9927_CR33","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al (2024) ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 30(11):3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6","journal-title":"Nat Med"},{"key":"9927_CR34","doi-asserted-by":"publisher","first-page":"e2300456","DOI":"10.1200\/PO.23.00456","volume":"8","author":"JA Shaw","year":"2024","unstructured":"Shaw JA, Page K, Wren E, de Bruin EC, Kalashnikova E, Hastings R, et al (2024) Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer. JCO Precis Oncol 8:e2300456. https:\/\/doi.org\/10.1200\/PO.23.00456","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"9927_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","volume":"22","author":"SV Lindskrog","year":"2025","unstructured":"Lindskrog SV, Strandgaard T, Nordentoft I, Galsky MD, Powles T, Agerbaek M, et al (2025) Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation. Nat Rev Urol 22(9):590\u2013608. https:\/\/doi.org\/10.1038\/s41585-025-01023-9","journal-title":"Nat Rev Urol"},{"issue":"1","key":"9927_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","volume":"5","author":"D Tougeron","year":"2025","unstructured":"Tougeron D, Louvet C, Desrame J, Evesque L, Angelergues A, Carnot A, et al (2025) Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. Commun Med 5(1):136. https:\/\/doi.org\/10.1038\/s43856-025-00867-x","journal-title":"Commun Med"},{"issue":"11","key":"9927_CR37","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/gutjnl-2024-331956","volume":"73","author":"C Campani","year":"2024","unstructured":"Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, et al (2024) Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Gut 73(11):1870\u201382. https:\/\/doi.org\/10.1136\/gutjnl-2024-331956","journal-title":"Gut"},{"issue":"1","key":"9927_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers15010157","volume":"15","author":"M Zhou","year":"2022","unstructured":"Zhou M, Bui N, Rathore R, Sudhaman S, George GV, Malashevich AK, et al (2022) Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma. Cancers 15(1):157. https:\/\/doi.org\/10.3390\/cancers15010157","journal-title":"Cancers"},{"issue":"2","key":"9927_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1078-0432.CCR-25-2312","volume":"32","author":"E Garralda","year":"2026","unstructured":"Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cardenas AB, et al (2026) Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clin Cancer Res 32(2):333\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2312","journal-title":"Clin Cancer Res"},{"issue":"3","key":"9927_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","volume":"8","author":"LM Weiss","year":"1984","unstructured":"Weiss LM (1984) Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8(3):163\u20139. https:\/\/doi.org\/10.1097\/00000478-198403000-00001","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"9927_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/106689690401200304","volume":"12","author":"M Bisceglia","year":"2004","unstructured":"Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, et al (2004) Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 12(3):231\u201343. https:\/\/doi.org\/10.1177\/106689690401200304","journal-title":"Int J Surg Pathol"},{"key":"9927_CR42","unstructured":"Mete O, Asa SL, Davis JL, Erickson L, et al (2023) Protocol for the Examination of Specimens From Patients With Adrenal Cortical Carcinoma. https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates. Accessed 20 June 2026"},{"issue":"17","key":"9927_CR43","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al (2021) FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res 27(17):4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327","journal-title":"Clin Cancer Res"},{"issue":"8","key":"9927_CR44","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al (2019) Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 5(8):1124\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0528","journal-title":"JAMA Oncol"},{"issue":"11","key":"9927_CR45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41571-025-01066-2","volume":"22","author":"AJ Medford","year":"2025","unstructured":"Medford AJ, Wander SA (2025) SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine. Nat Rev Clin Oncol 22(11):804\u2013805. https:\/\/doi.org\/10.1038\/s41571-025-01066-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"9927_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, et al (2021) Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 12(1):184. https:\/\/doi.org\/10.1038\/s41467-020-20493-6","journal-title":"Nat Commun"},{"issue":"3","key":"9927_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000351409","volume":"91","author":"J Wan","year":"2013","unstructured":"Wan J, Zhu L, Jiang Z, Cheng K (2013) Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma. Urol Int 91(3):273\u20138. https:\/\/doi.org\/10.1159\/000351409","journal-title":"Urol Int"},{"issue":"11","key":"9927_CR48","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/OP.24.00274","volume":"20","author":"J Xi","year":"2024","unstructured":"Xi J, Ma CX, O\u2019Shaughnessy J (2024) Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach. JCO Oncol Pract 20(11):1460\u201370. https:\/\/doi.org\/10.1200\/OP.24.00274","journal-title":"JCO Oncol Pract"},{"issue":"224","key":"9927_CR49","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"key":"9927_CR50","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1200\/JCO.2025.43.16_suppl.1010","volume":"43","author":"L Pusztai","year":"2025","unstructured":"Pusztai L, Scalise CB, Kalashnikova E, Glaberman UB, Ehsani S et al (2025) Circulating tumor (ct)DNA monitoring of ER+\/HER2- high-risk breast cancer during adjuvant endocrine therapy. J Clin Oncol 43:1010. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1010","journal-title":"J Clin Oncol"},{"issue":"13","key":"9927_CR51","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/1759-7714.15281","volume":"15","author":"Y Oh","year":"2024","unstructured":"Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, et al (2024) Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Thorac Cancer 15(13):1095\u2013102. https:\/\/doi.org\/10.1111\/1759-7714.15281","journal-title":"Thorac Cancer"},{"issue":"24","key":"9927_CR52","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, et al (2025) ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med 393(24):2395\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2511885","journal-title":"N Engl J Med"},{"issue":"4","key":"9927_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","volume":"75","author":"G Vandekerkhove","year":"2019","unstructured":"Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, et al (2019) Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 75(4):667\u201375. https:\/\/doi.org\/10.1016\/j.eururo.2018.12.042","journal-title":"Eur Urol"},{"issue":"1","key":"9927_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"30","author":"BG Sullivan","year":"2023","unstructured":"Sullivan BG, Lo A, Yu J, Gonda A, Dehkordi-Vakil F, Dayyani F, et al (2023) Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis. Ann Surg Oncol 30(1):278\u201384. https:\/\/doi.org\/10.1245\/s10434-022-12399-y","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"9927_CR55","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al (2019) Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res 25(14):4255\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3663","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9927_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al (2023) Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29(1):127\u201334. https:\/\/doi.org\/10.1038\/s41591-022-02115-4","journal-title":"Nat Med"},{"key":"9927_CR57","doi-asserted-by":"publisher","first-page":"1253629","DOI":"10.3389\/fonc.2023.1253629","volume":"13","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Shaverdian N, Eichholz JE, Kratochvil LB, McCune M, Murciano-Goroff YR, et al (2023) ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Front Oncol 13:1253629. https:\/\/doi.org\/10.3389\/fonc.2023.1253629","journal-title":"Front Oncol"},{"issue":"5","key":"9927_CR58","doi-asserted-by":"publisher","first-page":"1349-59 e2","DOI":"10.1016\/j.jtcvs.2024.01.017","volume":"168","author":"TK Martin","year":"2024","unstructured":"Martin TK, Dinerman A, Sudhaman S, Budde G, Palsuledesai CC, Krainock M, et al (2024) Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg 168(5):1349-59 e2. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.01.017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"9927_CR59","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","volume":"16","author":"MJ Elliott","year":"2025","unstructured":"Elliott MJ, Echelard P, Pipinikas C, Main S, Fuentes Antras J, Dou A, et al (2025) Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay. Nat Commun 16(1):1837. https:\/\/doi.org\/10.1038\/s41467-025-56658-4","journal-title":"Nat Commun"},{"issue":"18","key":"9927_CR60","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtroder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al (2019) Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol 37(18):1547\u201357. https:\/\/doi.org\/10.1200\/JCO.18.02052","journal-title":"J Clin Oncol"},{"issue":"24","key":"9927_CR61","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-25-1242","volume":"31","author":"T Akiyoshi","year":"2025","unstructured":"Akiyoshi T, Shinozaki E, Maeda Y, Taguchi S, Chino A, Hanaoka Y, et al (2025) Circulating Tumor DNA Longitudinal Analysis During Total Neoadjuvant Therapy and Non-operative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial. Clin Cancer Res 31 (24): 5188\u20135197. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1242","journal-title":"Clin Cancer Res"},{"key":"9927_CR62","doi-asserted-by":"publisher","unstructured":"Cohen SA, Aushev VN, Laliotis G, Jabbal IS, Nagarajan A, Wang C, et al (2025) Real-world monitoring of ctDNA reliably predicts cancer recurrence and treatment efficacy in patients with resected stages I-III colon cancer. Ann Surg. Published online August 7, 2025. https:\/\/doi.org\/10.1097\/SLA.0000000000006887","DOI":"10.1097\/SLA.0000000000006887"},{"issue":"19","key":"9927_CR63","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1158\/1078-0432.CCR-25-0512","volume":"31","author":"A Knisely","year":"2025","unstructured":"Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, et al (2025) Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clin Cancer Res 31(19):4122\u20134135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0512","journal-title":"Clin Cancer Res"},{"issue":"8","key":"9927_CR64","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","volume":"11","author":"J Taieb","year":"2025","unstructured":"Taieb J, Sullo FG, Lecanu A, Bourreau C, Barbier E, Gandini A, et al (2025) Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. JAMA Oncol 11(8):874\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2025.1646","journal-title":"JAMA Oncol"},{"issue":"1","key":"9927_CR65","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","volume":"16","author":"A Zaanan","year":"2025","unstructured":"Zaanan A, Didelot A, Broudin C, Laliotis G, Spickard E, Dutta P, et al (2025) Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun 16(1):6815. https:\/\/doi.org\/10.1038\/s41467-025-62056-7","journal-title":"Nat Commun"},{"issue":"12","key":"9927_CR66","doi-asserted-by":"publisher","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","volume":"13","author":"CA Parkinson","year":"2016","unstructured":"Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al (2016) Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med 13(12):e1002198. https:\/\/doi.org\/10.1371\/journal.pmed.1002198","journal-title":"PLoS Med"},{"issue":"11","key":"9927_CR67","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, et al (2022) Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med 28(11):2353\u201363. https:\/\/doi.org\/10.1038\/s41591-022-02047-z","journal-title":"Nat Med"},{"key":"9927_CR68","doi-asserted-by":"publisher","first-page":"e2400882","DOI":"10.1200\/PO-24-00882","volume":"9","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos PA, Cai M, Lee EK, Krasner C, Campos SM, Liu JF, et al (2025) Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole\/Abemaciclib in Endometrial Cancer. JCO Precis Oncol 9:e2400882. https:\/\/doi.org\/10.1200\/PO-24-00882","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"9927_CR69","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jmoldx.2024.07.001","volume":"26","author":"EM Alexander","year":"2024","unstructured":"Alexander EM, Miller HA, Egger ME, Smith ML, Yaddanapudi K, Linder MW (2024) The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden. J Mol Diagn 26(11):952\u201361. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.07.001","journal-title":"J Mol Diagn"},{"issue":"7","key":"9927_CR70","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1535-7163.MCT-19-1060","volume":"19","author":"AA Davis","year":"2020","unstructured":"Davis AA, Iams WT, Chan D, Oh MS, Lentz RW, Peterman N, et al (2020) Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Mol Cancer Ther 19(7):1486\u201396. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1060","journal-title":"Mol Cancer Ther"},{"key":"9927_CR71","doi-asserted-by":"publisher","first-page":"e2100512","DOI":"10.1200\/PO.21.00512","volume":"6","author":"MA Gouda","year":"2022","unstructured":"Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, et al (2022) Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 6:e2100512. https:\/\/doi.org\/10.1200\/PO.21.00512","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"9927_CR72","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","volume":"46","author":"M Pennanen","year":"2015","unstructured":"Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, Arola J (2015) Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol 46(3):404\u201310. https:\/\/doi.org\/10.1016\/j.humpath.2014.11.015","journal-title":"Hum Pathol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-026-09927-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:28:34Z","timestamp":1784950114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-026-09927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9927"],"URL":"https:\/\/doi.org\/10.1007\/s12022-026-09927-x","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to present the correct Supplementary Materials.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study\u00a0involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Texas MD Anderson approved this study (2025-0267). Informed consent was waived.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate and Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthew T. Campbell: Consulting\/Advisory Roles: \u2022 Eisai, Exelixis, Merck, Pfizer \u2022 Trials with Institutional Grant Support: \u2022 Exelixis, Pfizer, Janssen, AstraZeneca, Genentech \u2022 Non-branded educational programs: \u2022 Curio Science, Dava Oncology, MJH LifeSciences, OnViv Cancer Noetic. All other authors report no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31"}}